French‐Speaking Network of Pharmacogenetics ( RNPGx ) Recommendations for Clinical Use of Mavacamten

Abstract excerpt

Mavacamten, the first drug in the class of β-cardiac myosin modulator, is used for the treatment of patients with hypertrophic cardiomyopathy. This orally administered drug demonstrates wide interpatient variability in pharmacokinetics parameters, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 poor metabolizers have increased exposure and are at increased risk of reduced cardiac...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cardiomyopathy and Myosin Studies
• Share to Hormonal Regulation and Hypertension
• Share to Pharmacogenetics and Drug Metabolism